Biocad allowed clinical trials in Russia of vaccines against COVID-19

"The purpose of the clinical study: to assess the safety and immunogenicity of a vaccine for the prevention of coronavirus infection (COVID-19), a recombinant vector viral based on AAV5-RBD-S," reads the materials on the website of the state register of approvals for clinical trials.

It is noted that the dosage form of the drug is a solution for intramuscular administration.

In December last year, it was reported that biotech company Biocad began supplying COVID-19 vaccine to the center.

Hamaleas for vaccination in Russia.

Earlier, the head of the Russian Ministry of Health, Mikhail Murashko, said that a report on the results of clinical trials of the Russian vaccine against coronavirus infection Sputnik V would be prepared by October.